ATTO SEC Filings - Attovia Therapeutics, Inc. 10-K, 10-Q, 8-K Forms
Attovia Therapeutics (ATTO) SEC filings describe IPO-related conversions and insider/option activity. On Aug 6, 2026, Series A-1, A-2, B and C preferred converted to common on a 9.29:1 basis, and 782,854 Series B preferred converted into common. Redmile vehicles bought 600,000 shares at $17.00. Multiple directors and executives received stock options with $17.00 exercise price and 2027-2036 vesting.
How this was made
The 30-second read
Why it matters
Preferred stock automatically converted into common at a stated ratio upon IPO closing, while multiple insiders and directors received stock option grants with a $17.00 exercise price. These items can affect perceived insider alignment and near-term supply/demand dynamics, but the text does not provide new clinical or revenue guidance.
Market read
This is a primary-source disclosure of IPO closing mechanics and equity compensation grants, useful for understanding ownership structure and potential post-IPO trading behavior.
What to watch
Traders may focus on the $17.00 IPO price and conversion/ownership optics, but should also watch for subsequent 10-Q/10-K financials and any post-IPO financing or clinical updates not covered here.
Background
The page summarizes Attovia Therapeutics SEC filings tied to its Aug. 6, 2026 IPO closing, including 10-K/10-Q/8-K items and related equity transactions.
Ticker impact
Attovia Therapeutics disclosed IPO-related preferred-to-common conversions, insider option grants, and amended charter/bylaws effective Aug. 6, 2026.
Near-term impact likely limited, but conversion and insider option disclosures may influence sentiment and liquidity expectations around the IPO aftermath.
The article is an SEC-filing roundup describing primary corporate actions (conversion, charter/bylaws) and multiple option grants at a stated $17.00 exercise price, without new operating performance or guidance.
Market effects
Limited sector read-through; mostly company-specific IPO structure and governance updates.
No clear regional spillover beyond Nasdaq-listed small-cap IPO aftermath.
Primarily US-focused corporate actions; minimal global relevance.
Counterpoint
Because the disclosures are largely mechanical (conversion ratios, option grants, bylaws), they may not change fundamentals and could be over-weighted by short-term traders.
Key entities
- issuerAttovia Therapeutics, Inc.
Nasdaq-listed company (ATTO) whose IPO-related conversions, governance updates, and insider option grants are described.
- 10% owner/beneficial ownerRedmile Group (via managed vehicles)
Reportedly purchased additional common shares at $17.00 per share in connection with the IPO and is associated with preferred conversion.
- 10% owner/beneficial ownerFrazier Life Sciences XI, L.P.
Reported preferred-to-common conversions and an additional $17.00 per share common purchase on Aug. 6, 2026.
